ERBB2 and breast carcinoma: In this study, we employed a cell-SELEX method to accurately identify HER2-positive breast cancer cells, utilizing Sanger sequencing to determine a panel of DNA aptamers that bind to HER2 receptors on target cells with an equilibrium dissociation constant (Kd) in the nanomolar range.